|
 |
 |
| |
|
|
|
|
|
|
| |
About
Logos Technologies |
|
Logos
Technologies is a leading provider of world-class
integrated clinical trial solutions to
the worldís
pharmaceutical, biotechnology and clinical
research organisations. The ALPHADAS
Suite is a clinical study management
and fully
mobile Phase I proactive EDC system that
has been designed for real time eSource
data collection. The system provides
time based data entry at the bedside,
collection
and integration of laboratory data, images
and scans and Bar-coded labeling to track
samples from draw to dispatch. Logos
Technologiesí established and proven
product ALPHADAS
sets the standard in collecting Phase
I clinical trial data. ALPHADAS is
fully compliant with industry standards
and guidelines including FDA 21 CFR Part
11.
About OmniComm
OmniComm
Systems, Inc. provides customer-driven
Internet solutions
to
pharmaceutical, biotechnology, research
and medical device organizations that
conduct life changing clinical trial
research. OmniCommís growing base of
satisfied customers is a direct result
of the companyís commitment to deliver
products and services that ensure ease
of use, faster study build, ease of integration
and better performance. OmniCommís client
intuitive pricing model allows companies
that range from small to mid-size to
large scale institutions to safely and
efficiently capitalize on their clinical
research investments. OmniComm Systems,
Inc. has corporate headquarters in Ft.
Lauderdale, Florida with offices in Bonn,
Germany, Tula, Russia, California, Maryland,
New York, North Carolina and Texas. www.omnicomm.com
|
|
|
|
|
|
|
|
|
|
|
|
OmniComm
Systems, Inc. and Logos Technologies partner
to provide superior Electronic Data Capture
(EDC) Solutions for Phase I ñ IV Clinical
trials |
|
Leader
in integrated EDC solutions and time tested
experts in early Phase EDC join forces and
integrate their systems to expand the use of
EDC in Phase
I-IV studies.
|
|
|
|
|
|
FT. LAUDERDALE,
FL - April 4, 2008 - /MarketWire/ - OmniComm
Systems, Inc.
(OTC: OMCM.OB), a leader in integrated electronic
data capture (EDC) solutions for
clinical trials, today announced that OmniComm will
partner with Logos Technologies and create an integrated
solution with ALPHADAS®, the premier electronic
data capture solution designed specifically for Phase
I clinical trials. The combined technologies will
be available for use by customers using the TrialMasterÔ,
First in Functionality, EDC solution. The collaboration
will allow customers that are
conducting clinical research in Phase I to take advantage
of a clinical study management and fully mobile electronic
data capture system to capture data directly from
the patientís bedside. For those clients running
Phase I-IV clinical studies, the combination will
unify the capture, reporting, exporting and archival
of
clinical data into a common, costeffective, web-based,
user-interface. The final warehouse for data may
reside in SQL, Oracle ClinicalÆ database tables or
in SAS®.
"One
of the fastest growing segments for EDC adoption
in clinical trials is in the Phase I area. The report
from Health Industry Insights, U.S. Electronic
Data Capture 2006-2011- Spending Forecast
and Analysis, predicts that growth is expected to
more than double in the US alone over the next two
to three years," said Stephen Johnson, Chief Operating
Officer for OmniComm.
|
|
"The
interface between Logos Technologies and OmniComm
will offer a superior and dynamic EDC solution
for customers that are focused on Phase I clinical
trials and deliver an excellent addition to our
suite of targeted, integrated solutions for our
existing customers. The
integration of OmniCommís TrialMaster and Logos
Technologies ALPHADAS extends the capabilities
for data collected from ALPHADAS to be combined
with clinical data imported from other outside
sources. This combined data may then be exported,
archived and made available to our clients in
various reports and reporting formats. It also
offers
our clients running Phase I-IV clinical studies a
common, cost-effective, web-based, interface to
use across
their enterprise."
"Phase
I clinical studies are unique in the way that
they are conducted and they
need versatile solutions that are focused
on the challenges that are inherent to the Phase
I
setting. ALPHADAS first launched over 10 years
ago has assisted clients to run hundreds of studies
quicker and more efficiently said Giles Wilson,
Business and Operations Director for Logos. "The
need for real time data capture in Phase I studies
continues to increase, drug development companies
are looking for solutions that will produce faster
access to data and earlier go / no go decisions
while
reducing costs throughout the whole Phase
I process. The partnership between Logos Technologies
and OmniComm now offers companies a way to truly
benefit from EDC from the very onset of their trial
through to database lock."
For further information
please contact the Logos Technologies Press Office
by emailing here |
|
| |
|
|
|
|
 |
